Blinatumoab公司
医学
细胞因子释放综合征
重症监护医学
干预(咨询)
免疫疗法
淋巴细胞白血病
内科学
护理部
白血病
癌症
嵌合抗原受体
作者
Stephanie Szoch,Christina Boord,Alison Duffy,Ciera Patzke
出处
期刊:Journal of Infusion Nursing
[Ovid Technologies (Wolters Kluwer)]
日期:2018-06-29
卷期号:41 (4): 241-246
被引量:9
标识
DOI:10.1097/nan.0000000000000283
摘要
Blinatumomab has shown great potential for patients with chemotherapy-resistant B-cell acute lymphocytic leukemia. Blinatumomab's toxicity profile includes central nervous system toxicities, as well as cytokine release syndrome. Although neurological toxicities associated with blinatumomab are almost always reversible, early detection and intervention of these toxicities is vital to ensure that patients continue their full course of treatment. Guidelines for the preparation and administration of blinatumomab in both inpatient and outpatient settings, as well as a standardized neurological nursing assessment, were developed to ensure safe and effective administration of blinatumomab.
科研通智能强力驱动
Strongly Powered by AbleSci AI